Title: Sunitinib in renal-cell carcinoma: expanded indications
Abstract: Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trialIn a broad population of patients with metastatic RCC, the safety profile of sunitinib 50 mg once-daily (initial dose) on schedule 4-2 was manageable and efficacy results were encouraging, particularly in subgroups associated with poor prognosis who are not usually entered into clinical trials. Full-Text PDF
Publication Year: 2009
Publication Date: 2009-07-17
Language: en
Type: review
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 6
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot